JCTLM database for promoting the realization of
equivalent and consistent test results.
The review of biomedical reference materials and
the formulation of relevant reference methods and
measurement technical specifications are mainly the
responsibility of clinical medical measurement
technical committee and national reference material
management committee, which are responsible for
reviewing reference materials and reference methods
according to different division.
3.3 Interchangeability Evaluation
Due to the complexity of measurement methods and
measurement system composition in individual
differences of human body, there might be great
differences between reference materials and actual
samples, so biomedical reference materials pay more
attention to the interchangeability evaluation of
reference materials, The main purpose is to avoid the
lack of consistency between the actual sample
measurement results after the same biomedical
reference material calibrates different measuring
systems.
Interchangeability evaluation refers to the
characteristics of reference materials expressed by
the consistency between the measurement results
obtained by two given measurement procedures and
the measurement results obtained by another
specified substance for the specified amount of a
given reference material. It is more to compare with
the clinical trial data to ensure that the characteristics
of reference materials are consistent with the natural
samples, avoid the lack of comparability of
measurement results after calibrating different invitro
diagnostic systems.
The interchangeability results of biomedical
reference materials are closely related to the
evaluation methods. At present, the most widely used
interchangeability evaluation schemes are ep30-a,
ep14-a3 and IFCC schemes.
The validity standards of samples, measurement
procedures and measurement data used to evaluate
interchangeability are basically similar, but the
evaluation methods and judgment basis are slightly
different. Therefore, appropriate sample quantity,
type, sample status and evaluation method should be
selected according to specific conditions to ensure the
interchangeability on different in-vitro diagnostic
systems.
4 DIFFICULTIES AND
CHALLENGES
Biomedicine is developing rapidly at home and
abroad. It’s focus is mostly on the development of
clinical reference materials, measurement and
detection technology of measuring instruments for
biological analysis, molecular biological reference
materials and clinical application. Biomedical
reference materials emerge one after another, and
biometric technologies and methods have also been
significantly improved.
Although many biomedical reference materials
have been applied in biomedicine, clinical laboratory,
inspection and quarantine and other fields, there are
still many difficulties and challenges, such as:
1) Traceability: many characteristic values of
reference materials are given in the form of mass
fraction, molar concentration, etc., but there are few
reference materials in non-SI units.
2) Valuation Technology: the valuation method of
biomedical reference materials is complex, which
requires expensive experimental equipment and
consumables, and the development cost is high.
Although the existing fluorescence quantitative PCR
technology has been widely used, many
experimenters did not evaluate the applicability of the
method and optimize the test scheme in the
development process. In fact, nucleic acid quality,
primers and amplification efficiency directly affect
the measurement results. So, it is necessary to
strengthen the formulation of evaluation and
preparation standards and specifications.
3) Raw materials: the raw materials of many
biomedical reference materials come from blood,
urine, etc., with great individual differences. It is
difficult to ensure a stable source. Some enzyme
active reference materials are easy to denature, which
leads to the shortage of active components.
4) High-accuracy biomedical reference materials:
The focus of this part is to develop peptide and
protein reference materials for cardiovascular and
renal disease diagnostic markers and related auxiliary
diagnostic reference materials; Through high-
throughput gene sequencing technology, we should
study gene fragments for specific diseases, lock
individual lesion genes, formulate personalized
treatment plans, establish gene sequencing
measurement methods, and carry out the
development of high-accuracy and high-grade
reference materials to ensure the accuracy and
reliability of sequencing results and provide guidance
for the implementation of targeted therapy.